T1	Participants 60 95	patients with head and neck cancer.
T2	Participants 164 204	patients with head and neck cancer (HNC)
T3	Participants 399 432	patients with stage III or IV HNC
T4	Participants 768 802	21 RTOG HNC trials (1997 to 2002).
T5	Participants 996 1088	471 patients in RTOG 0129 (2002 to 2005) with known human papillomavirus and smoking status.
